Loading patent…
AssigneeLytix Biopharma AS
InventorsLiv Tone Eliassen, Gerd Berge, Baldur Sveinbjørnsson, John Sigurd Svendsen, Øystein Rekdal
Estimating the term…
The present invention provides a cytotoxic 7 to 25 mer peptide with three or more cationic residues which has one or more non-genetic bulky and lipophilic amino acids, as well as esters, amides, salts and cyclic derivatives thereof as well as methods of preparing the peptides, pharmaceutical compositions containing them and their use as medicaments, particularly as antibacterions or antitumoral agents. In a preferred aspect, the invention provides the use of said peptides in a method of inducing adaptive immunity against tumor growth or establishment in a subject, as well as the use of other lytic agents in a method of inducing adaptive immunity in a subject.
A method of inducing adaptive immunity against tumour growth or establishment in a subject having a tumour, comprising administration of an effective amount of a lytic peptide to said subject, wherein said peptide is from 7 to 25 amino acids in length, has three or more cationic residues, and includes one or more groups which are bulky and lipophilic, and whereby adaptive immunity against tumour growth or establishment is induced.
Dependencies are inferred from the claim text.